Anti-VEGF protein compositions and methods for producing the same

Patent metadata

Field	Value
Publication number	US-12012444-B2
Application number	US-202318116166-A
Country	US
Kind code	B2
Filing date	Mar 1, 2023
Priority date	Dec 6, 2019
Publication date	Jun 18, 2024
Grant date	Jun 18, 2024

Abstract

The present disclosure pertains to compositions comprising anti-VEGF proteins.

First claim

What is claimed is:

1. A culture media composition comprising chemically defined media (CDM) and aflibercept, wherein said aflibercept includes about 0.02% to about 1% oxidized aflibercept and wherein said oxidized aflibercept is oxidized at one or more amino acid residues selected from the group consisting of tryptophan, histidine and a combination thereof.

2. The culture media composition of claim 1 , wherein said aflibercept includes between about 0.02% and about 0.5% oxidized aflibercept.

3. The culture media composition of claim 1 , wherein said oxidized aflibercept includes His19 residue oxidation.

4. The culture media composition of claim 3 , wherein a relative abundance of the oxidized His19 residue is at least about 0.02%.

5. The culture media composition of claim 1 , wherein said oxidized aflibercept includes His86 residue oxidation.

6. The culture media composition of claim 5 , wherein a relative abundance of the oxidized His86 residue is at least about 0.02%.

7. The culture media composition of claim 1 , wherein said oxidized aflibercept includes His95 residue oxidation.

8. The culture media composition of claim 7 , wherein a relative abundance of the oxidized His95 residue is at least about 0.03%.

9. The culture media composition of claim 1 , wherein said oxidized aflibercept includes His110 residue oxidation.

10. The culture media composition of claim 9 , wherein a relative abundance of the oxidized His110 residue is at least about 0.04%.

11. The culture media composition of claim 1 , wherein said oxidized aflibercept includes His145 residue oxidation.

12. The culture media composition of claim 11 , wherein a relative abundance of the oxidized His145 residue is at least about 0.19%.

13. The culture media composition of claim 1 , wherein said oxidized aflibercept includes His203 residue oxidation.

14. The culture media composition of claim 1 , wherein said oxidized aflibercept includes His209 residue oxidation.

15. The culture media composition of claim 14 , wherein a relative abundance of the oxidized His209 residue is at least about 0.11%.

16. The culture media composition of claim 1 , wherein said oxidized aflibercept includes Trp58 residue oxidation.

17. The culture media composition of claim 16 , wherein a relative abundance of the oxidized Trp58 residue is at least about 0.03%.

18. The culture media composition of claim 1 , wherein said oxidized aflibercept includes Trp138 residue oxidation.

19. The culture media composition of claim 18 , wherein a relative abundance of the oxidized Trp138 residue is at least about 0.02%.

Assignees

• Regeneron Pharma

Inventors

• Wang Shunhai
• Li Ning
• Chen Hunter
• Bhupender Bhalla Amardeep Singh
• Lawrence Shawn M
• Johnson Amy S
• Casey Meghan
• Grapel Jaimie

Classifications

• C12N2529/10

  Stimulation by light · CPC title

• C12N15/85

  for animal cells · CPC title

• C07K1/06

  using protecting groups or activating agents {(C07K1/003, C07K1/006 take precedence)} · CPC title

• C12N2510/02

  Cells for production · CPC title

• C07K1/165

  mixed-mode chromatography · CPC title